Stay updated on Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial
Sign up to get notified when there's something new on the Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial page.

Latest updates to the Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThe webpage has been updated to include new information about a clinical trial for Recurrent Plasma Cell Myeloma, including the addition of a new registry identifier and collaborators, while significant details about the trial's objectives and treatment regimen have been removed.SummaryDifference42%
- Check34 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to February 25, 2025.SummaryDifference0.3%
- Check70 days agoChange DetectedThe webpage has added several new dates and a document related to informed consent from M.D. Anderson Cancer Center, while removing outdated dates and a notice about service performance issues.SummaryDifference4%
- Check92 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check99 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
Stay in the know with updates to Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial page.